Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.36 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.36 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MITF | O75030 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7551197 | 0.84 | KMT2A (0.62) | KMT2AMEN1L3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL24100866 | 0.84 | L3MBTL1 (0.43) | KMT2AMEN1L3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL24100835 | 0.80 | USP7 (0.44) | KMT2AMEN1ALDH1A1CYP1A2CYP2C9 | |
| SCHEMBL24101218 | 0.79 | L3MBTL1 (0.48) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL24100741 | 0.78 | MEN1 (0.46) | KMT2AMEN1L3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL24101123 | 0.76 | MEN1 (0.60) | KMT2AMEN1L3MBTL1ALDH1A1CYP1A2 | |
| SCHEMBL24101216 | 0.74 | L3MBTL1 (0.65) | KMT2AMEN1L3MBTL1CYP1A2CYP2C9 | |
| SCHEMBL24101228 | 0.74 | POLB (0.43) | KMT2AL3MBTL1ALDH1A1MAPTTP53 | |
| SCHEMBL23319917 | 0.69 | RHEB (0.40) | KMT2AMEN1CYP1A2CYP2C9RHEB | |
| SCHEMBL22609331 | 0.69 | ILK (0.57) | KMT2AMEN1ALDH1A1CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233533-A1 | COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION | HEALTH RESEARCH, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233533-A1 | COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION | HEALTH RESEARCH, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230233533-A1 | COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION | HEALTH RESEARCH, INC. (US) | 2023-07-27 | — | — | US | disclosed |
| WO-2021252068-A1 | COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION | HEALTH RESEARCH, INC. (US) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233533-A1 | COMPOSITIONS, METHODS OF TREATING AND PREVENTING FUNGAL INFECTIONS, AND METHODS OF INHIBITING PRP8 INTEIN EXPRESSION | PRPF8, PRPF40A, PRPF19 | KMT2A 3617/4885MEN1 936/4885L3MBTL1 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.